Based upon the peak sales of the topical product Penlac ($125 million US, 5.5%-8.5% efficacy) and Lamisil ($1.2 billion world-wide, 38% efficacy, but with the risk of liver failure and death), we believe a topical drug that is both safe and effective can generate peak sales of $700 million by 2020 in the U.S."
The product, 8% ciclopirox hydroxypropyl-chitosan nail lacquer (CicloPoli, Polichem), or P-3051, had an overall 119% greater mycologic cure rate than the commercially available 8% ciclopirox monoester (Penlac, Sanofi-Aventis).
Ciclopirox (Penlac), one of the more efficacious treatments, achieves a cure rate of 5.5%-8.5%, and the buildup of the lacquer vehicle requires frequent nail debridement.
In addition, the company has launched a generic version of Penlac topical solution (ciclopirox topical solution), a nail lacquer used to treat fungal infections of the fingernails and toenails.